BioNTech SE (BNTX) stock
BNTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Mar 10, 2026Score 3/30
$84.86−0.40 (-0.47%)
Close on Nov 17, 2026Market cap $21.32BP/E –Yield –
BioNTech r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was €2.10B, down 6.6% from the year before. The highest annual figure on record is €2.25B in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | €2.10B | -6.6% |
| FY2024 | Dec 31, 2024 | €2.25B | +26.4% |
| FY2023 | Dec 31, 2023 | €1.78B | +16.0% |
| FY2022 | Dec 31, 2022 | €1.54B | +61.9% |
| FY2021 | Dec 31, 2021 | €949.20M | +47.2% |
| FY2020 | Dec 31, 2020 | €645.00M | +184.8% |
| FY2019 | Dec 31, 2019 | €226.50M | +58.3% |
| FY2018 | Dec 31, 2018 | €143.04M | +67.3% |
| FY2017 | Dec 31, 2017 | €85.50M | – |
See a number that looks wrong?